BAN2401
BAN2401
BAN2401 is an investigational monoclonal antibody being developed for the treatment of Alzheimer's disease. It is designed to target and neutralize amyloid beta (Aβ) protofibrils, which are believed to play a key role in the pathogenesis of Alzheimer's disease.
Mechanism of Action[edit | edit source]
BAN2401 works by binding to soluble Aβ protofibrils, preventing their aggregation into amyloid plaques. These plaques are characteristic of Alzheimer's disease and are thought to contribute to neurodegeneration and cognitive decline. By targeting these protofibrils, BAN2401 aims to reduce the formation of amyloid plaques and potentially slow the progression of the disease.
Clinical Development[edit | edit source]
BAN2401 is being developed by Eisai Co., Ltd. in collaboration with Biogen. The drug has undergone several phases of clinical trials to evaluate its safety, tolerability, and efficacy in patients with Alzheimer's disease.
Phase I Trials[edit | edit source]
The initial phase I trials focused on assessing the safety and pharmacokinetics of BAN2401 in healthy volunteers and patients with mild to moderate Alzheimer's disease. These studies helped determine the appropriate dosing regimen for subsequent trials.
Phase II Trials[edit | edit source]
In the phase II clinical trial, BAN2401 demonstrated a statistically significant reduction in amyloid plaques and a slowing of cognitive decline in patients with early Alzheimer's disease. The trial used a novel Bayesian adaptive design to optimize the dosing and evaluate the drug's efficacy.
Phase III Trials[edit | edit source]
Phase III trials are currently underway to further assess the long-term safety and efficacy of BAN2401 in a larger population of patients with early Alzheimer's disease. These trials aim to confirm the findings from the phase II study and provide additional data on the drug's impact on disease progression.
Potential Impact[edit | edit source]
If successful, BAN2401 could represent a significant advancement in the treatment of Alzheimer's disease. By targeting the underlying pathology of the disease, it has the potential to modify the course of the illness rather than merely addressing the symptoms.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
Template:Alzheimer's disease treatments
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
